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Osteoporosis Index (MOI) was developed from Fracture Index (FI), a validated fracture risk score, to identify also osteoporosis.
MOIriskfactorsareage,weight,previous fracture, familyhistoryofhipfracture orspinalosteoporosis,smoking,shorteningofthe
stature, and use of arms to rise from a chair. The associationof these risk factors with BMD was examined in development cohorts
of 300 Finnish postmenopausal women with a fracture and in a population control of 434 women aged 65–72. Validation cohorts
included 200 fracture patients and a population control of 943 women aged 58–69. MOI identiﬁed femoral neck osteoporosis in
these cohorts as well as the Osteoporosis Self-AssessmentTool (OST).In the pooled fracture cohort, the associationof BMI-based
FRAX fracture risk with MOI was good. After BMD measurement, MOI identiﬁed well FRAX hip fracture risk-based Intervention
Thresholds (ITs) (AUC 0.74–0.90).
1.Introduction
Osteoporosis prediction rules attempt to select patients for
bonedensitometry. Arecent review updatestheperformance
of externally validated instruments that reported perfor-
mance characteristics in Cochrane Database between 2001
and 2009 [1]. Twenty-three studies of 14 instruments to
predict low BMD reported AUC estimates ranging mostly
between 0.6 and 0.8. Of these, Osteoporosis Self-Assessment
Screening Tool (OST) includes only age and weight but has
similar area under the ROC-curve (AUC) estimates as the
other more complicated instruments. Its validity in identi-
fying osteoporosis has been conﬁrmed in multiple indepen-
dent population cohorts both in men and women [1–3].
Most fractures occur in patients with normal or oste-
openic bone mass and instruments that predict low bone
density correlate only modestly with clinical fractures [1].
Fracture risk assessment tools use clinical risk factors (CRF)
to predict fractures, and combining bone densitometry with
risk score usually results in higher AUC estimates [1, 4].
Again, instruments with fewer risk factors often do as well
as those with more [1].
Recent meta-analyses and reviews have revealed the
main BMD-independentCRFsforosteoporosisfractures: in-
creasing age, low weight, previous fracture, family history
of osteoporosis fracture, smoking, glucocorticoid therapy,
neuromuscular disorders, and alcohol excess [5–10].
Fracture Index (FI) is a validated risk score for fracture
prediction in white women over the age of 65. It includes six
CRFs: increasing age over 65, fracture after age 50, maternal
hip fracture, weight below 58kg, smoking, and the use of
arms to rise from a chair test [11]. The recommendations
of the National Osteoporosis Foundation (NOF) for risk
assessment contain the ﬁrst 5 of these factors [12]. Also the
recent multiethnic Women’s Health Initiative (WHI) algo-
r i t h mp r e d i c t e dh i pf r a c t u r ew i t h i n5y e a r sa sw e l la sB M D .2 Journal of Osteoporosis
The WHI CRFsincludethe 5 factors above and, additionally,
general health, race, physical activity, corticosteroid use, and
diabetes [13].
WHO fracture risk assessment tool FRAX integrates
BMD with CRFs: age, weight/height (BMI), previous frac-
ture, parent fractured hip, current smoking, use of gluco-
corticoids, use of alcohol 3 or more units/day, rheumatoid
arthritis, and causes of secondary osteoporosis [14].
The aim of the present study was to develop from FI a
risk score which identiﬁes both fracture risk factors and low
BMD in Finnish population. We named this simple additive
score Mikkeli Osteoporosis Index (MOI), and compared the
correlation of MOI, FI, and OST with BMD. We further
c o m p a r et h ea b o v es c o r e sw i t hF R A Xf r a c t u r er i s ka n dt h e
concordance of MOI with FRAX to identify Intervention
Thresholds (ITs) proposed by the WHO Collaborating
Group [15–17].
2.Materialsand Methods
To obtain both epidemiological and clinical validity, we
usedtwoindependentdevelopmentcohorts(MikkeliCentral
Hospital fracture patient cohort and Kuopio Fracture Pre-
vention Study (FPS) population cohort) and two validation
cohorts(another Mikkelifracture patient cohort and Kuopio
population-based Osteoporosis Risk factor and Prevention
study (OSTPRE) cohort). Fracture patients and population
cohorts were recruited by separate research teams during
separate time periods.
2.1. Mikkeli Central Hospital Patient Cohorts (Development
and Validation Cohorts1). Between1.1.2002and 30.4.2005a
total of 698 consecutive female low energy fracture patients,
aged 45–79, who had fallen on the same level or from a
height of less than one meter were treated in Mikkeli Central
Hospital, Finland. Development Cohort 1 included 300 of
these, who accepted to participate in the study. Patients with
dementia, psychic instability, known secondary osteoporosis
(type I diabetes, rheumatoid arthritis, long-term glucocorti-
coiduse, malabsorptive syndromes) and women taking bone
active medications other than ovarian hormones, calcium,
or vitamin D were excluded. Thus, 180 out of 200 radius
fracture patients (90%) were prospectively included in the
study, as well as 24 patients with fracture of the proximal
humerus (40%), 21 clinical spine (87%), 23 hip (7%), and
52 other extremity fracture patients (61%). Patients with
fractures of hand or foot were excluded from the study.
The patients ﬁlled in a questionnaire with the FI risk fac-
tors, including family history of hip fracture or senile spinal
hump with shortening, and recalled height at age 30. Their
weight was measured with a digital calibrated scale and the
height with a calibrated wall meter. The ability to rise from a
chair without use of arms was tested. Hospital staﬀ nurses
registered and two osteoporosis nurses recorded the data.
BMD of lumbar spine and proximal femur was measured
with Lunar DPX-IQ. Patients provided an informed, written
consent to participate in the study. The study was approved
by the local ethics committee.
The next 200 consecutive low energy fracture patients,
treated in Mikkeli Central Hospital between 1.5.2005 and
1.10.2007, were used as a clinical validation cohort (Valida-
tion Cohort 1) for MOI. These included 104 radius fracture
patients, 20 with fracture of the proximal humerus, 9 clinical
spine, 5 hip, and 62 other low energy extremity fracture
patients. The process of recruitment and data collection was
otherwise identical with that of the ﬁrst 300 patients of the
Development Cohort 1.
2.2. Population-Based Development and Validation Cohorts 2.
These study populations included two separate independent
random densitometry samples selected from the prospective
Osteoporosis Risk Factor and Prevention (OSTPRE)-study
cohort: Development Cohort 2 and Validation Cohort 2.
The OSTPRE cohort was established in 1989 by selecting
all women born in 1932–1941 and resident in Kuopio
Province, Finland (n = 14220) [18].
The baseline postal questionnaire of the OSTPRE cohort
included questions about health disorders, medication, use
of hormone therapy (HT), gynaecological history, nutri-
tional habits, calcium intake, physical activity, alcohol con-
sumption, smoking habits, and anthropometric information
[18]. Five-year (in 1994–97), ten-year (1999–2001), and
ﬁfteen-year (2000–2003) follow-up questionnaires were sent
to the 13100 women who responded to the questionnaire at
baseline, with responses of 11954 (5-year), 11537 (10-year),
and 10926 (15-year).
As u b s a m p l e( n = 3222) of the 13100 baseline respon-
dents was resourced for central bone density measurements.
Of these,therandomised population-basedsample consisted
of 2025 women. In all, 1873 women of the random part
underwent the 5-year and 10-year bone density measure-
ments with Lunar DPX-IQ. Serial valid measurements for
neck of femur and lumbar spine were recorded for 1438
women in both baseline and follow-up measurements.
Patients with metallic implants or severe bone defor-
mities, including osteoarthritis with signiﬁcant osteophytes,
were excluded after a systematic manual review of densit-
ometry reprints by the research team physicians. Hysterec-
tomized women, for whom it was not possible to deﬁne
menopausal status, and premenopausally bilaterally ovariec-
tomized women were additionally excluded.Accordingly,the
ﬁnal Validation Cohort 2 consisted of the OSTPRE cohort
women with complete results of the BMD measurements
and FI risk factors in the 10-year follow-up study (N =
943, age 58–69 years). The FPS population (n = 5407)
was randomly selected in 2003 from the OSTPRE baseline
respondents (n = 13100) with a purpose to determine
the eﬀect of vitamin D and calcium in fall and fracture
preventioninpostmenopausalwomen.Theinclusioncriteria
for FPS study were age over 65 years, living in Kuopio
province at the inclusion time, and not belonging to the
original OSTPRE BMD-measurement sample. 3432 women
of the 5407 (63.5%), willing to participate in the prospective
vitamin D and calcium trial, were randomized into two
groups of equal size. FPS Cohort, a subsample of 434
women, aged 65–72 years, was randomly selected at theJournal of Osteoporosis 3
baseline (Development Cohort 2) and underwent detailed
measurement program. Risk factor analysis included stan-
dardizedheightandweightmeasurements,balancetests,grip
strength, and food, smoking, and physical activity diaries.
The adult height at age 30 and all recalled fractures during
adulthoodwere registered. A half way squatting test was used
i n s t e a do ft h eu s eo fa r m st or i s ef r o mac h a i rt e s t .T h e
baseline values of BMD and risk factors have been described
previously [19].
In FPS and OSTPRE studies, two specially trained
nurses carried out DXA measurements in Kuopio University
Hospital. Quality standards were tested on daily basis. The
short-term reproducibilityof this method has been shown to
be 0.9% for lumbar spine and 1.5% for femoral neck BMD
measurements. The long-term reproducibility (CV) of the
DXA instrument, as determined by regular phantom meas-
urements, was 0.4% [20]. BMD results were expressed as T-
scores based on the manufacturer’s reference database.
3.StatisticalMethods
The characteristics of the development cohort—BMD, age,
weight, height loss, and FI risk factors—were compared
using t-test and chi-square test. To compare potential risk
factors by age, the fracture cohort was dichotomized into age
groups of 45–64 and 65–79 years.
BMD, age, weight, and height loss were examined as
continuous variables in the development cohorts. Other
CRFs were dichotomized (yes/no) and were examined with
appropriate univariate statistical analyses. The age was
categorized into 5-year thresholds like in FI. Weight was
categorized into 5 groups to examine linearity of the asso-
ciation of weight and BMD. Height loss was categorized into
3 groups based on contextually and statistically meaningful
association withBMD.Continuous andcategorizedvariables
were compared with linear regression and ANOVA. To keep
theratio ofthe BMD-independentfracture risk factors stable
in the ﬁnal model, we multiplied the original FI risk factors
by2and alignedtheagethresholds with those ofFIin theage
range of 70–79. We named this simple additive score Mikkeli
Osteoporosis Index (MOI) and compared the correlation of
MOI, FI, and OST with BMD. We plotted the ROC curves
of MOI, FI, and OST for identifying osteopenia (T-score≤
−1.5 or ≤− 2.0) and osteoporosis (T-score≤− 2.5 either in
f e m o r a ln e c k ,t o t a lh i p ,o rs p i n e( L2 – 4a r e a ) )b o t hi nt h e
developmentand validation cohorts. The diﬀerence between
the AUC values was tested with univariate z-score test. The
results were considered signiﬁcant at P<. 05 level. We used
Excel 96 and SPSS Windows 11.5 statistical programs.
To obtain true clinical relevance, we pooled the fracture
cohorts and calculated with FRAX-UK-tool the Body Mass
Index-based FRAX 10-year major osteoporosis fracture risk
(FRAX-BMI) of each fracture patient (N = 500). Using
regression analysis, we compared MOI, FI, and OST with
FRAX-BMI.
We further compared the concordance of MOI, after
BMD-measurement, to identify BMD-based FRAX 10-year
fracture risk (FRAX-BMD)ITs inthe pooled fracture cohort.
We used the smoothed 10-year hip fracture probabilities
presented for the UK and Australia by Borgstr¨ om et al.
[17], which were approximated to integer. For MOI, we
used three groups: low risk (no treatment), intermediate risk
(treatment based on BMD result), and high risk (treatment
without BMD measurement) (Table 4). We calculated the
identiﬁcation characteristics between the three MOI risk
groups and the seven risk thresholds of FRAX-BMD.
4.Resultsand Discussion
4.1. Development of the Score. The mean age of the Mikkeli
Central Hospital 300 fracture patients (DevelopmentCohort
1) was 65 ± 9 years. Femoral neck BMD (BMD-N) was
normal (T-score over −1SD) in 11–18% of the patients
and osteoporotic (T-score ≤− 2.5SD) in 35–40%. Fracture
patients under the age of 65 had more osteoporosis in
their family and smoked more than patients above age 65
(Table 1).
Univariate analysis was performed both in fracture
patient cohort (Development Cohort 1) and in the FPS
population(DevelopmentCohort 2).Femoralneckand total
hip BMD were associated with weight, age, height loss,
and previous fracture, in decreasing order of importance
(Table 2). The association of BMD with age was linear,
whereas the association of BMD with weight disappeared
nonlinearly above 80 kg. Categorizing continuous variables
(age, weight, and shortening) did not signiﬁcantly change
the association. Hip BMD was associated, additionally, with
the use of arms to rise from a chair test and family history,
but with smoking only in fracture patients above age 65
(Table 2).
In multivariate linear regression models, these associ-
ations with BMD remained stable; only shortening of the
stature lost its value in fracture patient cohort (data not
shown).
Based on the above analyses, we included 7 factors in
MOI:age55–59/60–64/65–69/70–74/75years.(1/2/3/4/6risk
points), weight below 80/71/64/58kg (1/2/3/4p), previous
adultfracture,familyhistoryofhipfractureorspinal osteoporo-
sis and smoking (2p each), shortening by 3/5cm (1/2p), and
use of arms to rise from a chair (2p), max 20p.
The AUC values to identify osteoporosis in the femoral
neck in the diﬀerent cohorts are presented in Table 3.I nt h e
total hip and spine (L 2–4) areas, the AUCs for osteoporosis
in the diﬀerent cohorts were 0.72–0.78 and 0.66–0.74
with MOI, 0.59–0.71 and 0.59–0.65 with FI and 0.56–0.75
and 0.59–0.73 with OST, correspondingly. The diﬀerences
between scores were mostly not statistically signiﬁcant.
In the OSTPRE validation controls at age 58–69, the
AUC increased signiﬁcantly from osteopenia to osteoporosis
(AUC BMD-N −1.5/−2.5: MOI 0.63/0.79, FI 0.59/0.76 and
OST0.59/0.74).Inthefracture validationpatients, thescores
operated identically at BMD-levels −2.5 and −2, but not at
all at BMD-level −1.5 (data not shown).
4.2. Comparison of MOI with FRAX in the Pooled Fracture
Cohort. In regression analysis, the association of MOI with4 Journal of Osteoporosis
Table 1: BMD and prevalence of risk factors (%) in the development patient cohorts.
Development Cohort 1 (Fracture patients) Development Cohort 2 (FPS)
Age < 65y, N = 141 Age 65y, N = 159 Age 65–72y N = 434
Age (mean, SD) 57 5y 71 4y 68 2y
BMD-N −0.9, 0.3∗∗∗ −1.6, 0.9 −1.6, 0.9
BMD-H −1.2, 0.4∗∗∗ −1.5, 0.9 −1.5, 0.9
BMD-S −1.4, 0.9 −1.5, 1.3 −1.5, 1.3
%% %
Osteoporosis 35∗∗∗ 40∗∗∗ 14
Osteopenia 47 49 47
BMD normal 18∗∗∗ 11∗∗∗ 39
Weight ≤ 57kg 18∗∗∗ 13 8
Previous fracture 15
Family history of hip fracture or spinal osteoporosis 34∗∗∗ 15 14
Current smoker 18∗∗∗ 45
No regular exercise/walking 18∗ 16∗∗ 10
Shortening 5cm 2 22∗∗∗ 4
Shortening 3-4cm 14 26∗ 18
Use of arms to rise from a chair 11 18∗∗∗ 6
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001, signiﬁcant diﬀerence against FPS cohort.
BMD-N: bone mineral density (T-score), femoral neck.
BMD-H: bone mineral density (T-score), proximal femur.
BMD-S: bone mineral density (T-score), spine L 2–4.
FPS: Fracture Prevention Study.
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Figure 1: Correlation of MOI with Body Mass Index-based FRAX
10-year major osteoporosis fracture risk in the pooled fracture
cohort (N = 500) (R2 = 0.54, F = 596 ). (x = MOI, y = FRAX).
FRAX-BMI was highly signiﬁcant in the pooled fracture
cohort (R2 = 0.54, F = 596, N = 500, Figure 1). The
association of FI and OST with FRAX-BMI was poor (R2 for
FI versus OST in the pooled fracture cohort were 0.08 versus
0.01).
The smoothed intervention thresholds by FRAX-BMD
and the corresponding MOI thresholds are presented
in Table 4. The characteristics of diagnostic concordance
between MOI and FRAX-BMDinthe pooled fracture cohort
are presented in Table 5. The sensitivity of MOI was high
and the speciﬁcity moderate. Those patients in the fracture
cohort which were identiﬁed as false positives by MOI
fulﬁlled the FRAX treatment threshold with a mean of 77
(55–93)%.69%(16outof26)ofthefalse negativepatientsin
the fracture cohort, unidentiﬁed by MOI, had BMD > −1.5.
Our aim was to validate a score that identiﬁes both low
BMD and independent fracture risk factors. The score was
developed within low energy fracture patients in Mikkeli,
Finland, with the assistance of a separate population-based
control group (FPS). It was validated in two independent
cohorts, both in fracture patients and in population-based
controls (OSTPRE). The risk score, named MOI, is a
modiﬁcationofthepreviously introducedFI. MOIidentiﬁed
both low BMD and classiﬁes patient ITs in concordance with
FRAX.
There were limitations in the development of MOI. The
participation rate of hip or humerus fracture patients in
this prospective study was low because of high age, frailty,
or dementia. The development and validation cohorts were
independent ofeach otherbutwere of the same geographical
region. The population-based FPS development cohort had
only a narrow age range, and therefore the eﬀect of age
on BMD could be analysed only in fracture patients.
The size of the fracture Validation Cohort 2 was limited,Journal of Osteoporosis 5
Table 2: Proportion of variance in BMD in Development Cohort 1
(fracture patients, N = 300, age 45–79) and Development Cohort
2( F P S ,N = 434, age 65–72). R2 value (%), explained by the risk
factors in univariate regression models, and by MOI, FI, and OST-
scores.
Fracture patients
N = 300 R2;B M D - N R2;B M D - H R2;B M D - S
Weight, continuous 0.14∗∗∗ 0.19∗∗∗ 0.12∗∗∗
Weight, categorized 0.13∗∗∗ 0,17∗∗∗ 0.12∗∗∗
Age, continuous 0.13∗∗∗ 0.07∗∗∗ 0.01
Age, categorized 0.12∗∗∗ 0.07∗∗∗ 0.0
Shortening, continuous 0.08∗∗∗ 0.06∗∗∗ 0.02∗
Shortening, categorized 0.05∗∗∗ 0.03∗ 0.01
Family history 0.01 0.0 0.0
Smoking 0.0 0.01 0.01
Rise from a chair test 0.0 0.02∗ 0.0
MOI 0.22∗∗∗ 0.22∗∗∗ 0.0
FI 0.08∗∗∗ 0.07∗∗∗ 0.0
OST 0.25∗∗∗ 0.25∗∗∗ 0.0
FPS
N = 434 R2;B M D - N R2;B M D - H R2;B M D - S
Weight, continuous 0.05∗∗∗ 0.12∗∗∗ 0.09∗∗∗
Weight, categorized 0.06∗∗∗ 0.12∗∗∗ 0.09∗∗∗
Age, continuous
Age, categorized
Shortening, continuous 0.01∗ 0.01 0.01
Shortening, categorized 0.03∗∗∗ 0.03∗∗∗ 0.02∗∗
Fracture history 0.03∗∗∗ 0.03∗∗∗ 0.04∗∗∗
Family history 0.0 0.01∗ 0.0
Smoking 0.0 0.0 0.01
Rise from a chair test 0.0 0.02∗ 0.0
MOI 0.11∗∗∗ 0.17∗∗∗ 0.11∗∗∗
FI 0.04∗∗∗ 0.06∗∗∗ 0.03∗∗
OST 0.06∗∗∗ 0.12∗∗∗ 0.19∗∗∗
MOI: Mikkeli Osteoporosis Index; FI: Fracture Index; OST: Osteoporosis
Self-AssessmentTool. Other abbreviations, see Table 1.
Table 3: AUC values (standard error) for MOI, FI, and OST with
osteoporosis (BMD-T-score≤− 2.5) at the femoral neck in the
development FPS (age 65–72, n = 434) and fracture cohorts (age
45–79, N = 300) and in the validation fracture cohort (N = 200)
and OSTPRE validation cohort (age 58–69, n = 943).
FPS cohort
age 65–72
Fracture
development
cohort
Fracture
validation
cohort
OSTPRE
cohortage
58–69
MOI 0.67 (0.06) 0.75 (0.03) 0.67 (0.07) 0.79 (0.04)
FI 0.56 (0.06) 0.68 (0.04) 0.53 (0.08) 0.76 (0.04)
OST 0.63 (0.06) 0.79 (0.03)∗ 0.62 (0.07) 0.74 (0.05)
∗P<. 05, signiﬁcant diﬀerence between OST and FI.
MOI: Mikkeli Osteoporosis Index.
FI: Fracture Index.
OST: Osteporosis Self-AssessmentTool.
but it represents typical clinical white female patients in
which osteoporosis CDRs would be applied. Both control
Table 4: Intervention thresholds by FRAX-BMD presented for
UK and Australia (smoothed 10-year hip fracture probabilities,
%) and the corresponding MOI thresholds, used for diagnostic
comparison.
FRAX risk (%)
Age, y. UK Australia
50 1 2
55 2 3
60 3 4
65 4 5
70 5 7
75 6 10
80 7 10
MOI score
No treatment 0–4 0–5
Treatment by BMD 5–11 6–12
Fracture patients T < −1.5T < −2
Patients without fracture T < − 2T < −2.5
Treatment without BMD 12 13
Table 5: Characteristics of diagnostic concordance between MOI
and FRAX-BMD to identify Intervention Thresholds presented for
UK and Australia (see Table 4).
Pooled fracture patients (N = 500)
MOI characteristics UK Australia
False− 26 16
True− 205 327
True+ 165 96
False+ 7 61
LR+ 2.7 5.4
LR− 0.14 0.17
Sensitivity (%) 91 86
Speciﬁcity (%) 66 84
AUC (%) 74 90
LR+: positive likelihood ratio.
LR−: negative likelihood ratio.
AUC: area under the ROC curve.
groups were representative population-based cohorts with
a high participation rate and long followup. Two specially
trained nurses registered and collected the control group
data, whereas staﬀ nurses registered and two osteoporosis
nurses only collected the corresponding data in the clinical
fracture series. Also, misinterpretations of the densitometry
reprints were excludedin the populationcohorts, which may
explainthehigherAUCsforosteoporosisidentiﬁcationinthe
OSTPRE population controls.
FI registers only low weight < 58kg. In our study,
the relation between weight and BMD was nonlinear. In
WHO meta-analysis, low BMI below 20 had a twofold hip
fracture risk compared to BMI of 25. The risk levelled oﬀ
in nonlinear fashion as BMI increased to 30 [8]. FI includes
postmenopausal fractures above age 50, and NOF treatment6 Journal of Osteoporosis
recommendations include fractures above age 40 [11, 12].
FRAX and MOI include all previous adult fractures because
theseindicatean increasedrisk forlaterfractures (RR1.8–2.0
both in men and women) [6].
FI and FRAX include only maternal/parental hip frac-
tures, while MOI includeship fracture and spinal osteoporo-
sis in all ﬁrst-degree relatives. In WHO meta-analysis, any
parental or sibling osteoporosis fracture increased the risk
of subsequent hip and osteoporosis fractures independent
of BMD (RR 1.5–2.3) [7]. Also, our research team recently
identiﬁed an association between increased fracture risk in
perimenopausal women and their sisters’ fracture history
[21].
Awareness of height loss and changing body proﬁle is
considered to increase patient compliance [22]. Height loss
by 2–5 cm increases the risk of hip fractures and risk of
silentandclinicalvertebralfractures [23,24].Heightlosswas
independently predictive of hip fractures in the WHI study
[13] and is a risk factor in the EPOS fracture algorithm [25].
MOI, FI, and NOF treatment recommendations all have
the same ﬁve CRFs, which have been identiﬁed also in recent
meta-analyses and reviews [6–10]. They were also good
predictors of actual occurrence of fractures in a cohort of
postmenopausal women followed prospectively for up to 22
years [26]. The FI risk factors identiﬁed fractures also in the
prospective multisite Canadian CANDOO clinical patient
cohort [27].
The FRAX Tool is based on the above meta-analyses and
has been validated in large independent prospective cohorts.
It calculates the 10-year probability of fractures in several
countries [15, 17]. ITs based on major osteoporosis fracture
risk instead of hip fracture risk seem to increase sensitivity of
identiﬁcation in younger age groups [16].
However, recent data from prospective FIT and SOF-
study population cohorts of elderly white women suggest
that even more simple models, based on age, femoral neck
BMD, and fracture history predict clinical fracture as well
as more complex FRAX models [28, 29]. These ﬁndings,
however, require conﬁrmation in other cohorts of younger
women or men and diﬀerent geographic settings. Our pro-
spective fracture cohorts represent typical clinical white
female patients in which osteoporosis CDRs would be
applied. 284 patients in the pooled cohort (N = 500) had
a radius fracture. In these patients, the three risk groups of
MOIseem, afterBMDmeasurement, toidentify ITs similarly
tothesevenage/riskthresholds ofFRAX-BMD.The majority
of false negative patients in the fracture cohort, unidentiﬁed
by MOI, had BMD > −1.5. Bisphosphonate therapy has
not been demonstrated to be eﬀective with femoral neck T-
scores better than −1.5. In women with osteopenia below
T−1.5 therapy is cost-eﬀective in USA after additional
BMD-independent fracture risk factors that confer a BMD-
adjusted relative fracture risk of 2.0 or higher [30].
MOI is currently in clinical use in themajority of Finnish
central hospital districts. Its advantage is that it identiﬁes
osteoporosis and fracture risk factors with a single ﬁgure:
lowrisk, MOI0–5/6(notreatment), intermediate risk (treat-
ment based on BMD result), and high risk, MOI>11/12
(treatment without BMD measurement). The intermediate
risk group to identify patients for BMD measurement can
be adjusted according to national variations in fracture
incidence and diagnostic and treatment resources.
5.Conclusions
MOI identiﬁes osteoporosis and fracture risk factors with
a single ﬁgure and, after BMD measurement, Intervention
Thresholds in concordance with FRAX.
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